Three biopharma companies became publicly traded companies and made their debut on the Nasdaq this week.
Oyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.
Shares of Cellectis Therapeutics were up in trading after the gene-editing pioneer company forged a deal with Cambridge, Mass.-based Cytovia Therapeutics to develop immunotherapies based on gene-edited allogeneic CAR T-cells.
Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.
Myovant Sciences’ stock rocketed on news that the company was partnering with Pfizer to develop and commercialize Orgovyx (relugolix) for prostate cancer and women’s health.
Auris Medical shares skyrocketed after the announcement of lab test results that appeared to show the company’s nasal spray AM-301 could potentially protect users against Covid-19, according to Business Insider.
Pfizer Inc. received informal requests relating to operations in China from the U.S. Department of Justice and the U.S. Securities and Exchange Commission in June and August, respectively, according to a regulatory filing from the company.
Cytokinetics’ stocks plummeted after the company released topline results from a Phase III cardiovascular clinical trial with partners Amgen and Servier in which the secondary endpoint to prove potential to save lives failed.
Through a definitive merger agreement, BridgeBio acquired 36.3 percent of Eidos Therapeutics’ outstanding common stock that it did not already own.
In an effort to raise up to $400 million, Vesper Healthcare Acquisition Corporation set a $10.00 per-unit price of the company’s initial public offering (IPO) of 40 million units